Biomarkers to guide clinical therapeutics in rheumatology?
Biomarkers to guide clinical therapeutics in rheumatology?
复制标题
DOI：
10.1097/bor.0000000000000250
复制
发表时间：
2016-03
影响因子：
5.1
通讯作者：
Mao R
中科院分区：
文献类型：
--
作者：
Robinson WH;Mao R
在风湿病学中使用生物标志物可以帮助识别疾病风险，改善诊断和预后，靶向治疗，评估对治疗的反应，并进一步了解疾病的潜在发病机制。在这里，我们讨论了风湿性疾病生物标志物的最新进展，该领域进展的现有障碍，以及生物标志物实现精准医学从而改变风湿病学的潜力。尽管仍然存在重大挑战，但在风湿性疾病的生物标志物发现和开发方面仍在继续取得进展。下一代技术的使用，包括大规模测序，蛋白质组学技术，代谢组学技术，质谱细胞术和其他单细胞分析和多分析物分析技术，已经产生了一系列新的候选生物标志物。然而，这些生物标志物仍然需要严格的验证，并且尚未进入临床实践和治疗开发。本文综述了过去12个月生物标志物领域的进展以及仍然存在的挑战。更好的生物标志物，理想的机制，需要指导临床决策在风湿病学。尽管下一代生物标志物发现技术的使用正在取得进展，但我们必须克服寻找新生物标志物的障碍，以识别具有更大诊断和预测效用的生物标志物。鉴定具有强大诊断和预测效用的生物标志物将使风湿病学的精确医学成为可能。
The use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology. Although significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain. Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.